ACTRN12622000873729已完成4 期
Efficacy and safety of artemether-lumefantrine for the treatment ofuncomplicated Plasmodium falciparum malaria in Nangarhar andLaghman, Afghanistan.
Ministry of Public Health Afghanistan0 个研究点目标入组 123 人开始时间: 2022年6月20日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 123
研究概览
简要总结
A total of 123 (63 Laghman and 60 in Nangarhar) eligible patients were recruited. All patients reached study endpoints during the follow-up, and achieved adequate clinical and parasitological response. No adverse events were recorded. No resistance markers for artemisinin, piperaquine and mefloquine were observed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 6 Months 至 o limit（—）
- 性别
- All
入选标准
- •1. Aged between 6 months and above with the exception of 12-17 years old female minors and unmarried females above 18 years and above;
- •2. Mono-infection with P. falciparum detected by microscopy;
- •3. Parasitaemia of 500 – 200000 per microL asexual forms;
- •4. Presence of axillary or tympanic temperature greater or equal to 37.5 degrees centigrade or history of fever during the past 24 h;
- •5. Ability to swallow oral medication;
- •6. Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- •7. Informed consent from the patient or from a parent or guardian in the case of children aged less than 18 years;
- •8. Informed assent from any minor participant aged from 12 to 17 years; and
- •9. Consent for pregnancy testing from married female aged 18 years and above
排除标准
- •1. Presence of general danger signs in children aged under 12 years or signs of severe falciparum malaria according to the definitions of WHO;
- •2. Weight under 5 kg;
- •3. Haemoglobin below 8 g per dl;
- •4. Mixed or mono-infection with another Plasmodium species detected by microscopy;
- •5. Presence of severe malnutrition defined as a child aged 6-60 months who has a mid-upper arm circumference below 115 mm);
- •6. Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- •7. Regular medication, which may interfere with antimalarial pharmacokinetics;
- •8. History of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
- •9. A positive pregnancy test or breastfeeding of married women aged 18 years and above; and
- •10. Unable to or unwilling to take pregnancy test or to use contraception for women of child-bearing age and who are sexually active.
研究者
相似试验
已完成
4 期
Efficacy and safety of Artemether-Lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in different sentinel site in SudaMalariaACTRN12622000930785Ministry of Health212
已完成
4 期
Efficacy and safety of artemether- lumefantrine and artesunate - amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mainland TanzaniaInfection - Studies of infection and infectious agentsMalariaACTRN12622001243707ational Institute for Medical Research176
已完成
4 期
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Al Tor Bin Qais in Hajah, Yemen.Infection - Studies of infection and infectious agentsMalariaACTRN12624000526572The Ministry of Public Health and Population88
已完成
4 期
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in two sites in Yemen.Infection - Studies of infection and infectious agentsMalariaACTRN12617000283370Ministry of Public Health and Population110
已完成
不适用
Treatment of Non-falciparum MalariaAcute Non-falciparum MalariaNCT00725777Albert Schweitzer Hospital40